Galectin Therapeutics (GALT) Expected to Announce Quarterly Earnings on Friday

Galectin Therapeutics (NASDAQ:GALT) is expected to be announcing its Q3 2026 results on Friday, November 13th. Analysts expect Galectin Therapeutics to announce earnings of ($0.05) per share for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.05). On average, analysts expect Galectin Therapeutics to post ($0.30) EPS for the current fiscal year and ($0.23) EPS for the next fiscal year.

Galectin Therapeutics Trading Down 2.7%

GALT opened at $3.29 on Thursday. Galectin Therapeutics has a 12 month low of $2.03 and a 12 month high of $7.13. The company has a market cap of $216.68 million, a PE ratio of -7.65 and a beta of 0.53. The company has a 50 day moving average of $3.70 and a 200 day moving average of $3.22.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on GALT. Weiss Ratings restated a “sell (d-)” rating on shares of Galectin Therapeutics in a research report on Monday, September 14th. Zacks Research raised Galectin Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $11.00.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies that target galectin-3, a protein associated with fibrosis, inflammation and immune regulation. The company’s research is aimed at treating serious chronic diseases in which galectin-3 may contribute to disease progression. Its lead investigational product is belapectin, also known as GR-MD-02, a galectin-3 inhibitor being studied primarily for liver diseases, including nonalcoholic steatohepatitis (NASH), now commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH), and related cirrhosis complications such as portal hypertension.